QT prolongation is a delay in the electrical reset of the heart between beats, visible on an electrocardiogram (ECG) as a stretched-out interval between two specific waveforms. It matters because this delay creates a window in which the heart’s lower chambers can fall into a chaotic, sometimes fatal rhythm called torsades de pointes. The condition can be inherited, triggered by medications, or provoked by something as correctable as low potassium or magnesium levels, and it sits at the intersection of genetics, pharmacology, and emergency medicine in ways that affect millions of prescriptions every year.
What Happens Inside the Heart
Every heartbeat involves a carefully timed sequence of electrical events. Ions flow into heart muscle cells to trigger contraction, and then different ions flow out to reset the cell for the next beat. That resetting phase is called repolarization, and the QT interval on an ECG is essentially a measurement of how long repolarization takes across the ventricles. Several potassium channels drive this process. One, known as the slowly activating delayed rectifier current, plays a major role in repolarization of the cardiac action potential.1PubMed. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation Another potassium current, carried by a channel called hERG, is particularly important because it is uniquely vulnerable to interference from drugs and genetic mutations.2PubMed. Contributions of HERG K+ current to repolarization of the human ventricular action potential
When these channels are blocked or malfunction, potassium flows out of the cell more slowly, and repolarization drags on. The QT interval stretches. During that extended vulnerable window, stray electrical signals called early afterdepolarizations can fire, effectively re-triggering parts of the heart muscle before the rest has finished resetting. If those extra signals propagate unevenly across ventricle tissue with patchy repolarization, the result is torsades de pointes, a twisting, spiraling rhythm that can degenerate into ventricular fibrillation and cardiac arrest.3PubMed Central. Mechanisms of torsades de pointes: an update Research in animal models has shown that a rise in intracellular calcium is what actually triggers these early afterdepolarizations, and that they can originate from multiple sites simultaneously, creating the chaotic pattern seen on the ECG.4PubMed Central. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome
How It Is Measured and Why the Formula Matters
Because the QT interval naturally shortens when your heart beats faster, raw QT measurements need to be adjusted for heart rate before they mean anything clinically. That adjusted value is called the QTc, the “c” standing for “corrected.” The trouble is that there are several correction formulas in wide use, and they do not all perform equally well.
The oldest and still most commonly applied formula, developed by Bazett in 1920, overcorrects at high heart rates and undercorrects at low ones. In a large database study of normal ECGs, about 30 percent of those ECGs would be flagged as abnormally prolonged using Bazett’s formula with the traditional 440-millisecond cutoff, compared with fewer than 2 percent using Fridericia, Framingham, or Hodges corrections.5PubMed. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs That is an enormous rate of false positives. A separate study confirmed that Bazett-corrected values were more variable over both short and long time periods than values from Fridericia and Framingham corrections, meaning Bazett introduces noise into serial monitoring.6Scientific Reports. Influence of heart rate correction formulas on QTc interval stability
When researchers directly compared how well each formula predicted death, Fridericia and Framingham came out on top. In one study, prolonged QTc by the Framingham formula predicted 30-day mortality with a hazard ratio over 7, versus under 5 for Bazett.7PubMed Central. Which QT Correction Formulae to Use for QT Monitoring? The practical consequence is that Bazett overestimates how many patients have dangerous QT prolongation, which can lead to unnecessarily withholding first-choice medications. Despite this, Bazett’s formula remains embedded in clinical practice and many automated ECG printouts, so anyone reading their own report should understand that the number at the bottom of the page may be exaggerated if their heart rate was above about 70 beats per minute.
Why So Many Drugs Cause QT Prolongation
The hERG potassium channel has an unusual structural quirk that makes it a magnet for drug molecules. Most potassium channels have a narrow internal cavity, but hERG features hydrophobic pouches branching off its central pore that can accommodate a wide variety of chemical structures.8Trends in Pharmacological Sciences. hERG K+ Channels: Structure, Function, and Clinical Significance The amino acids lining this cavity have been mapped through mutation studies, revealing that the binding site is both large and flexible, able to stretch around bigger molecules via a hinge region in one of the channel’s structural segments.9PubMed. Drug block of the hERG potassium channel: insight from modeling The channel’s gating behavior, how it opens and closes, also influences drug access to the binding site, which helps explain why some drugs that look chemically safe still get trapped inside and block current flow.10PubMed. hERG potassium channels and the structural basis of drug-induced arrhythmias
This architectural openness is why QT prolongation shows up as a side effect in drug classes that have nothing to do with the heart. Class I and Class III antiarrhythmic drugs prolong the QT interval by design, but the same effect turns up as an unwanted surprise with certain antibiotics, antihistamines, opioid analgesics, and even some complementary medicines.11Prescriber Update. Drug-induced QT prolongation and Torsades de Pointes A cross-sectional study of non-cardiac drugs associated with QT prolongation identified 42 distinct medications across six therapeutic groups, with proton pump inhibitors, specifically esomeprazole, accounting for close to half the cases, followed by antimicrobials like azithromycin.12PubMed Central. Predictive Analysis of Non-Cardiac Drug-Induced QTc Interval Prolongation: A Cross-Sectional Study Among antiemetics, the differences are dramatic: ondansetron carried a QT-related reporting signal roughly three times that of olanzapine in a large adverse-event database, which led the FDA to restrict its high-dose intravenous formulation, while a related drug, palonosetron, appears to have minimal QT effect.13PubMed. Antiemetic-Associated QT Prolongation: A Clinical Review and Risk-Stratified Prescribing Framework for Long QT Syndrome
Who Is More Vulnerable
Women have a longer baseline QTc than men and appear to be more sensitive to drugs that prolong the interval. In a controlled study using sotalol, a well-known QT-prolonging drug, baseline QTc was 10 to 15 milliseconds longer in women. When the drug was given, the largest increase in QTc was roughly 68 milliseconds in women versus 27 milliseconds in men, and the relationship between drug concentration and QT change was steeper in women even after accounting for the fact that women reached higher blood levels of the drug.14PubMed Central. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol The reasons for this sex difference involve hormonal effects on ion channel expression, and it means that standard QTc thresholds for “prolonged” are set differently for men and women, typically around 450 milliseconds for men and 460 for women on most clinical guidelines.
Electrolyte disturbances amplify the risk from any QT-prolonging trigger. Low potassium and low magnesium both impair the same repolarization currents that drugs block, so the effects compound. Patients on diuretics, those with chronic vomiting or diarrhea, and people with kidney disease are at particular risk. Elevated body temperature and acidic blood pH can also modify the interaction between drugs and the hERG channel, increasing arrhythmia risk in critically ill patients who may already be on multiple QT-prolonging medications.
On the genetic side, congenital long QT syndrome involves inherited mutations in the genes encoding the very ion channels that drugs target. Hundreds of mutations across more than a dozen genes have been catalogued, with the three most common subtypes accounting for the majority of cases.15PubMed. The genetic basis of long QT and short QT syndromes: a mutation update People who carry one of these mutations may have a normal or borderline QTc under resting conditions but develop dangerous prolongation when exposed to a drug, a fever, or an electrolyte shift that a person without the mutation would tolerate without incident. This hidden genetic susceptibility explains some of the seemingly random cases of severe drug reactions in otherwise healthy individuals.
Beyond the QTc Number
Clinicians have been searching for ECG markers that capture arrhythmia risk better than the QTc alone. One candidate is the interval between the peak and the end of the T-wave, known as the Tpeak-to-Tend interval, which reflects how unevenly different layers of the heart wall are repolarizing. A study of sudden cardiac death cases found that the mean Tpeak-to-Tend interval was about 89 milliseconds in people who died suddenly, compared with about 76 milliseconds in matched controls, and this difference held up after adjusting for age, sex, QTc, and heart function.16PubMed Central. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death In patients with hypertrophic cardiomyopathy, each 10-millisecond increase in this interval was associated with a 63 percent higher risk of dangerous ventricular arrhythmias.17PubMed. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy
The practical limitation is that how you measure this interval matters. Its predictive value for ventricular arrhythmias depends on the specific measurement method and whether heart rate correction is applied, though for predicting death specifically, most published methods seem to perform similarly.18EP Europace. Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention For now, Tpeak-to-Tend remains more of a research tool than a routine clinical measurement, but it highlights the reality that a single corrected QT number cannot capture all the electrical complexity that determines who actually develops a dangerous rhythm.
Treatment When Things Go Wrong
Intravenous magnesium sulfate is the first-line treatment for torsades de pointes. In one of the earliest systematic reports, a single 2-gram bolus completely stopped the arrhythmia within one to five minutes in nine of twelve consecutive patients, and the remaining three responded after a second bolus.19PubMed. Treatment of torsade de pointes with magnesium sulfate A more recent scoping review across multiple studies found that torsades resolved in about 78 percent of patients treated with intravenous magnesium, with no serious adverse events from the magnesium itself. The caveat: roughly 22 percent of patients progressed to ventricular fibrillation despite magnesium, underscoring the need for a defibrillator at the bedside during treatment.20PubMed Central. Safety and Efficacy of Intravenous Magnesium for Torsade de Pointes ― A Scoping Review ― Beyond magnesium, managing torsades involves stopping the offending drug, correcting potassium levels, and sometimes using temporary cardiac pacing to speed up the heart rate and shorten the QT interval.
For people with congenital long QT syndrome, long-term management starts with beta-blockers, with propranolol and nadolol being the most effective options. With few exceptions, all carriers of pathogenic mutations should be treated because of the risk of sudden death during a first cardiac event.21Pharmacology & Therapeutics. Pharmacological and non-pharmacological management of the congenital long QT syndrome: The rationale About one in five patients continue to have fainting spells despite beta-blockers, and for them, a surgical procedure called left cardiac sympathetic denervation can be highly effective. One study of patients who underwent this procedure through a minimally invasive approach found that the mean number of cardiac events per year dropped from about 2.1 to 0.3, and the average QTc shortened from 560 to 491 milliseconds.22PubMed. Video-thoracoscopic left cardiac sympathetic denervation for long-QT syndrome Implantable defibrillators are reserved for the highest-risk patients, since they come with their own complications, especially in young people who may live with the device for decades.
QT Prolongation in Cancer Treatment
The rise of targeted cancer therapies has introduced a new population of patients at risk. Tyrosine kinase inhibitors, a class of drugs now central to treating cancers from leukemia to kidney cancer, cause significant QTc prolongation and are associated with an increased risk of cardiac events.23PubMed Central. The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs) These drugs can affect the heart both directly, through ion channel blockade, and indirectly through intracellular signaling pathways, making their cardiac toxicity less predictable than that of older QT-prolonging drugs.24PubMed Central. Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7
The good news, if it can be called that, is that torsades de pointes in the setting of cancer treatment remains genuinely rare, and most patients can continue their medications safely with appropriate monitoring.25PubMed. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics The challenge is that cancer patients are often on multiple QT-prolonging drugs simultaneously, including antiemetics and antibiotics, while also dealing with electrolyte imbalances from chemotherapy-related nausea and vomiting. The result is a population where QT monitoring needs to be more aggressive than usual, and where the risk-benefit calculation of continuing a life-saving cancer drug with known QT effects has to be weighed carefully against the small but real chance of a cardiac arrhythmia.
How Drug Regulation Changed Because of QT Prolongation
The history of drug-induced QT prolongation reshaped pharmaceutical regulation. The antihistamine terfenadine, widely sold over the counter in the late 1980s and early 1990s, was found to cause QT prolongation and torsades de pointes when blood levels rose due to overdose or impaired liver metabolism. Its active metabolite, fexofenadine, turned out to have virtually no hERG-blocking activity and did not prolong the QT interval. The availability of this safer alternative led to terfenadine’s removal from the market in 1998.26PubMed Central. Molecular Determinants of hERG Channel Block by Terfenadine and Cisapride Other drug withdrawals followed, and the cumulative impact prompted the International Council for Harmonisation to release guidelines in 2005 requiring both nonclinical hERG testing and clinical “thorough QT” studies for virtually all new drugs.27PubMed Central. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)
These thorough QT studies are expensive, requiring hundreds of healthy volunteers hooked up to ECG monitors after receiving the drug, a positive control, and a placebo. Updated guidelines have introduced more flexible approaches, including concentration-QTc modeling as a primary analysis method and the possibility of using strong nonclinical safety data to reduce or waive the dedicated clinical QT study.28PubMed Central. FDA’s insights: implementing new strategies for evaluating drug-induced QTc prolongation The regulatory apparatus around QT prolongation is arguably the most rigorous safety framework applied to any single side effect in all of drug development. It has undeniably prevented harmful drugs from reaching the market, but critics argue it has also killed promising drug candidates that would have been safe in practice, since hERG binding in a lab dish does not always translate into clinically meaningful QT prolongation in humans.
Detection in Newborns
Long QT syndrome can present before birth. Fetal arrhythmias, including sinus bradycardia, heart block, and even torsades de pointes, can be the first clue. In a study of 43 fetuses showing arrhythmias consistent with long QT syndrome, slow heart rate was the most common finding. Among those who developed torsades de pointes in the fetal or newborn period, postnatal cardiac arrest or sudden death occurred despite treatment in several cases.29PubMed Central. Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome The stakes are high but the numbers are small: congenital long QT syndrome affects roughly one in 2,000 to 2,500 live births, and only a fraction present with arrhythmias in utero.
Detecting QT prolongation in newborns on standard monitoring equipment has historically been difficult because of their fast heart rates and small signal amplitudes. Researchers have developed automated algorithms specifically adapted for neonatal ECGs, with adjusted thresholds and specialized handling of the rapid rates typical in this population. Testing in neonatal intensive care units showed that continuous automated QT monitoring in newborns is both feasible and accurate, raising the possibility of earlier identification of at-risk infants.30PubMed. An algorithm for QT interval monitoring in neonatal intensive care units
Artificial Intelligence and QT Monitoring
Traditional QT monitoring requires a skilled human to read an ECG, pick the right leads, identify the end of the T-wave (which can be ambiguous), and apply a correction formula. Machine learning is beginning to automate and potentially surpass this process. One AI model, called QTNet, was trained on ECG waveforms to predict drug-induced QT prolongation in outpatients and achieved an area under the curve of about 0.80, outperforming models that relied on clinical risk factors or baseline QTc alone. Its performance held up over time periods as long as six months.31JACC: Clinical Electrophysiology. QTNet: Predicting Drug-Induced QT Prolongation With Artificial Intelligence–Enabled Electrocardiograms
A separate study found that machine learning models using gradient-boosted trees and deep neural networks could predict QT prolongation at the time of prescribing with areas under the curve around 0.87, identifying higher-risk patients before they even start the offending medication.32Heart Rhythm. Machine learning–enabled assessment of risk of drug-induced QT prolongation at the time of prescribing Perhaps most intriguingly, deep learning models analyzing the overall shape of the ECG waveform, rather than just measuring QTc, could detect exposure to QT-prolonging drugs with far greater accuracy than QTc alone (area under the curve of 0.98 versus 0.72 for QTc). These same models could also identify patients with congenital long QT syndrome, particularly the type involving the hERG channel, suggesting that the full ECG waveform contains information about repolarization risk that a single number cannot capture.33European Heart Journal. Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome The clinical deployment of these tools is still early, but they represent a shift from asking “is the QTc above a threshold” to asking “what does the entire electrical signature of this heart tell us about vulnerability.”